Due to increasing payer budget pressure and stakeholder demands for evidence of a new therapy’s value, the hurdle to gain reimbursement for innovative products are much higher today.
Today's payers demand that products demonstrate COMPARATIVE CLINICAL EFFECTIVENESS AND ECONOMIC VALUE or risk not being reimbursed. Today, non-coverage moratoriums are commonplace in the U.S. private payer marketplace.
Gone are the days where biopharmaceutical companies with products in early development can delay pricing and reimbursement considerations just prior to launch and expect premium pricing without payer considerations strategically addressed early on in the clinical and commercial development work.
To be successful in today’s market, products must be able to provide;
Relevant comparator and end points that are meaningful to payers
Evidence-based value propositions that resonate with all key stakeholders
Pricing and payer contracting that is consistent with the product’s value and underlying commercial strategy, while minimizing cross-border risks
A country-based strategy that can successfully tackle the technical complexity and political nuisances of applying for and negotiating reimbursement in each type of payer system
-In maximizing global access and revenues, biopharmaceutical firms need strategic market access insights that extend beyond just the US and European markets;
Japan is the second biggest market for patented pharmaceuticals in the world after the US. Value Genome has deep expertise on Japan reimbursement pricing, including knowledge of the complex pricing rules and processes, government policy trends related to drug reimbursement, extensive experience estimating reimbursement price potential and developing strategy to maximize reimbursement. We are your best partner for understanding and succeeding with reimbursement price listing in Japan.
Affordability remains the number one barrier to access to innovative medicines in the emerging markets in Asia, Latin America, and Africa and the Middle East. Value Genome has firsthand experience in developing programs to maximize access to innovative medicines while optimizing revenue streams with win-win solutions. Researching and designing optimal patient access programs, tiered pricing by income, and other potential access solutions are part of Value Genome’s forte.”
Value Genome consultants are here to partner and assist your team in developing a strong pricing, reimbursement, and access strategy to ensure reimbursement listing and access for patients. Our goal is to help innovative biopharmaceutical firms in optimizing the financial return whether it’s providing product pricing valuation for a licensing or acquisition deal or assisting firms in their US and global product launches.